SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance

Jensen-Pergakes, K; Tatlock, J; Maegley, KA; McAlpine, IJ; McTigue, M; Xie, T; Dillon, CP; Wang, YL; Yamazaki, S; Spiegel, N; Shi, ML; Nemeth, A; Miller, N; Hendrickson, E; Lam, H; Sherrill, J; Chung, CY; McMillan, EA; Bryant, SK; Palde, P; Braganza, J; Brooun, A; Deng, YL; Goshtasbi, V; Kephart, SE; Kumpf, RA; Liu, W; Patman, RL; Rui, E; Scales, S; Tran-Dube, M; Wang, F; Wythes, M; Paul, TA

Paul, TA (通讯作者)，Pfizer Inc, Pfizer Oncol Res Unit, 10724 Sci Ctr Dr, San Diego, CA 92121 USA.

MOLECULAR CANCER THERAPEUTICS, 2022; 21 (1): 3

Abstract

Protein arginine methyltransferase 5 (PRMT5) overexpression in hematologic and solid tumors methylates arginine residues on cellular proteins involved......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索